Leukemia Research
Volume 24, Issue 4 , Pages 317-330 , April 2000

Cytokine modulated cell-membrane bound tumour necrosis factor expression is associated with enhanced monocyte-mediated killing of human leukaemic targets

  • Marc A. Williams

      Affiliations

    • Corresponding Author InformationCorresponding author. School of Medicine, Department of Paediatrics, Division of Paediatric Infectious Diseases, Centre for AIDS Research, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0672, USA. Tel.: +1-858-5347170; fax: +1-858-5347411
    • ,
  • Adrian C. Newland
    • ,
  • Stephen M. Kelsey

Received 2 June 1999 ,Accepted 16 October 1999.

References 

  1. Fischer DG, Hubbard WJ, Koren HS. Tumour cell killing by freshly isolated peripheral blood monocytes. Cell. Immunol. 1981;58:426–435
  2. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, interferon-γ and interleukin-1. Nature. 1986;323:86–89
  3. Woods KM, Chapes SK. Three distinct cell phenotypes of induced TNF cytotoxicity and their relationship to apoptosis. J. Leuk. Biol. 1993;53:37–44
  4. Kriegler M, Perez C, Defay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988;53:45–53
  5. Perez C, Albert I, Defay K, Zachariades N, Gooding L, Kriegler M. A non-secretable cell-surface mutant of tumour necrosis factor (TNF) kills by cell-to-cell contact. Cell. 1990;63:251–260
  6. Luttig B, Decker T, Lohmann-Matthes H. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral membrane protein and a molecule attached to its receptor. J. Immunol. 1989;143:4034–4038
  7. Wiegmann K, Scutze S, Kampen E, Himmler A, Machleidt T, Kronke M. Human 55 kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 1992;267:17997–18001
  8. Brakebusch C, Nophar Y, Kemper O, Engelmann H, Wallach D. Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling but not induced shedding of the receptor. EMBO J. 1992;11:943–950
  9. Engelmann H, Holtmann H, Brakebusch C, Avni Y, Sarov I, Nophar Y, et al. Antibodies to a soluble form of a tumor necrosis factor receptor have TNF-like activity. J. Biol. Chem. 1992;265:14497–14504
  10. Higuchi M, Aggerwal BB. Differential roles of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation and differentiation. J. Immunol. 1994;152:4017–4025
  11. Peck R, Brockhaus M, Frey JR. The principal tumor necrosis factor receptor in monocyte cytotoxicity is on the effector cell, not on the target cell. Cell. Immunol. 1991;132:308–318
  12. Heller RA, Song K, Fan N, Chang DJ. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 1992;70:47–56
  13. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilisation of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 1992;175:323–329
  14. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 1989;264:11974–11980
  15. Olsson I, Gatanga T, Gullberg U, Lantz M, Granger GA. Tumor necrosis factor (TNF) binding proteins (TNF receptor forms) with possible roles in inflammation and malignancy [Review]. Eur. Cytokine Network. 1993;4:169–180
  16. Metcalf D. The molecular biology and function of the granulocyte–macrophage colony-stimulating factors. Blood. 1986;67:257–267
  17. Nicola NA. Hematopoietic cell growth factors and their receptors. Annu. Rev. Biochem. 1989;58:45–77
  18. Isfort RJ, Ihle JN. Multiple haemopoietic growth factors signal through tyrosine phosphorylation. Growth Factors. 1990;2:213–220
  19. Kanakura Y, Druker B, Cannistra SA, Furukawa Y, Torimoto Y, Griffin JD. Signal transduction of the granulocyte-macrophage colony stimulating factor and IL-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 1990;76:706–715
  20. Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors. Cell. 1991;66:1165–1174
  21. Paquette RL, Zhou JY, Yang YC, Clark SC, Koeffler HP. Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood. 1988;71:1596–1600
  22. Yuo A, Kitegawa S, Motoyoshi K, Azuma E, Saito M, Takaku F. Rapid priming of human monocytes by human haemopoietic growth factors: granulocyte-macrophage colony stimulating factor (CSF), macrophage-CSF and interleukin-3 selectively enhance superoxide release triggered by receptor-mediated agonists. Blood. 1992;79:1553–1557
  23. Fabian I, Shapira E, Gadish M, Kletter Y, Nagler A, Flidel O, et al. Effects of Interleukin-3, macrophage and granulocyte-macrophage colony stimulating factor on monocyte function following autologous bone marrow transplantation. Leuk. Res. 1992;16:703–709
  24. Cannistra SA, Vallenga E, Groshek P, Rambaldi A, Griffin JD. Human granulocyte-macrophage colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a TNF-dependent mechanism. Blood. 1988;71:672–676
  25. Grabstein KH, Urdal DL, Tushinski R, Mochizuki, Price V, Cantrell MA, Gillis S, Conlon PJ, 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor: Science; 232:506–8.
  26. Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Newland AC. Administration of recombinant human granulocyte–macrophage colony stimulating factor (rHuGM-CSF) activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br. J. Haematol. 1995;90:31–40
  27. Williams MA, Kouromoussis I, Syndercombe-Court D, Hendry L, Newland AC, Kelsey SM. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy regulates the expression and secretion of monocyte tumor necrosis factor (TNF) and TNF receptors p55 and p75. Blood. 1995;86:4234–4242
  28. Williams MA, Newland AC, Kelsey SM. Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br. J. Haematol. 1997;98:960–968
  29. Williams MA, White SA, Miller JJ, Toner C, Withington S, Newland AC, et al. Granulocyte-macrophage colony stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J. Infect. Dis. 1998;177:107–115
  30. Williams MA, Withington S, Newland AC, Kelsey SM. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J. Infect. Dis. 1998;178:1421–1433
  31. Rosner G. Fundamentals of Biostatistics (edition 3). Boston MA, PWS-Kent, 1999.
  32. Holtmann H, Hahn T, Wallach D. Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology. 1988;177:7–22
  33. Peck R, Brockhaus M, Frey JR. Cell surface tumour necrosis factor (TNF) accounts for monocyte and lymphocyte-mediated killng of TNF-resistant target cells. Cell. Immunol. 1989;122:1–10
  34. van de Loosedrecht AA, Beelan RHB, Ossenkopple GJ, Broekhoven MG, Langenhuijsen MMAC. Cellular and cytokine dependent monocyte-mediated leukemic cell death:modulation by interferon gamma and TNF. Exp. Hematol. 1993;21:461–468
  35. Hasday JF, Shah EM, Liebermann AP. Macrophage tumor necrosis factor release is induced by contact with some tumors. J. Immunol. 1990;145:371–379
  36. Yamauchi T, Sagawa T, Kanoh M, Utsami S. Lymphokine-independent, leukemia cell-mediated induction of tumor necrosis factor in human monocytes. Cancer Res. 1990;50:2708–2712
  37. Buckle AM, Joyarum K, Hogg N. Colony stimulating factors and interferon gamma differentially affect cell surface molecules shared by monocytes and neutrophils. Clin. Exp. Immunol. 1990;81:339–344
  38. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J. Med. Vet. Mycol. 1996;34:63–69
  39. Takahashi GW, Andrews GF 3rd, Lilly MB, Singer JW, Alderson MR. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood 1993;81:357–64.
  40. Khwaja A, Addison IE, Johnson B, Yong K, Linch DC. Interleukin-3 administration enhances human monocyte function in vivo. Br. J. Haematol. 1994;88:515–519
  41. Oster W, Lindemann A, Mertelsmann R, Hermann F. GM-CSF and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood. 1989;73:64–67
  42. Maurer AB, Ganser A, Buhl R, Seipelt G, Ottmann OG, Mentzel U, et al. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia. 1993;7:1728–1733
  43. Wiltschke C, Krainer M, Wagner A, Linkesch W, Zielinski CC. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp. Hematol. 1995;23:402–406
  44. Cannistra SA, Rambaldi A, Spriggs DR, Hermann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell-line and by normal human monocytes. J. Clin. Invest. 1987;79:1720–1728
  45. Sisson SD, Dinarello CA. Production of interleukin-1α, interleukin-1β and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 1988;72:1368–1374
  46. Kohn FR, Philips GL, Lingemann HG. Regulation of tumor necrosis factor alpha production and gene expression in monocytes. Bone Marrow Transplant. 1992;9:369–376
  47. Rhoades KL, Cai S, Golub SH, Economou JS. Granulocyte-macrophage colony-stimulating factor and interleukin-4 differentially regulate the human tumor necrosis factor-alpha promoter region. Cell. Immunol. 1995;161:125–131
  48. Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim. Biophys. Acta. 1988;948:151–159
  49. Munn DH, Cheung NKV. Phagocytosis of tumor cells by human macrophages cultured in recombinant human macrophage colony stimulating factor. J. Exp. Med. 1990;172:231–237
  50. Green SJ, Chen TY, Crawford RM, Nacy CA, Morrison DC, Meltzer MS. Cytotoxic activity and production of toxic nitrogen oxides by macrophages treated with IFN-α and monoclonal antibodies against the 73-kDa lipopolysaccahride receptor. J. Immunol. 1992;149:2069–2075
  51. Zarling JM, Shoyab M, Marquardt H, Hansom MB, Lioubin MN, Todaro GJ. Oncostatin-M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proceed. Nat. Acad. Sci. USA. 1986;83:9739–9743
  52. Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 1998;28:257–263
  53. Wong GWH, Tartaglia LA, Lee MS, Goeddel DV. Antiviral activity of tumor necrosis factor (TNF) is signalled through the 55-kDa type I TNF receptor. J. Immunol. 1992;149:3350–3353
  54. Fahlman C, Jacobsen FW, Veiby OP, McNiece IK, Blomhoff HK, Jacobsen SE. Tumor necrosis factor-alpha (TNF-alpha) potently enhances in vitro macrophage production from primitive murine haemopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors. Blood. 1994;84:1528–1533
  55. Nashleanas M, Kanaly S, Scott P. Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 1998;160:5506–5513
  56. Salkowski CA, Detore G, McNally R, van Rooijen N, Vogel SN. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J. Immunol. 1997;158:905–912
  57. Takakuwa T, Knopf HP, Sing A, Carsetti R, Galanos C, Freudenberg MA. Induction of CD14 expression in LPSn, LPSd and tumor necrosis factor receptor-deficient mice. Eur. J. Immunol. 1996;26:2686–2692
  58. Kitagawa S, Yuo A, Yagisawa M, Azuma E, Yoshida M, Furukawa Y, et al. Activation of human monocyte function by tumor necrosis factor: rapid priming for enhanced release of superoxide and erythrophagocytosis, but no direct triggering of superoxide release. Exp. Hematol. 1996;24:559–567
  59. van der Poll T, Calvano SE, Kumar A, Braxton CC, Coyle SM, Barbosa K, et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood. 1995;86:2754–2759
  60. Williams MA, Kelsey SM, Newland AC. GM-CSF and stimulation of monocyte/macrophage function. In vivo relevance and in vitro observations. Eur. J. Cancer. 1999;35(3):S18–S23(Suppl.)
  61. Wiltchke C, Krainer M, Wagner A, Linkesch W, Zielinski CC. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp. Hematol. 1995;23:402–406
  62. Wing EJ, Magee M, Whiteside T, Kaplan S, Shadduck R. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of TNF and interferon in cancer patients. Blood. 1989;73:643–646
  63. Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, et al. Monocyte activation following systemic administration of human granulocyte–macrophage colony-stimulating factor. J. Immunother. Emphasis Tumor Immunol. 1994;16:132–141
  64. Faradji A, Bohbot A, Schmitt-Goguel M, Siffert JC, Dumont S, Wiesel ML, et al. Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow elutriation for adoptive cellular immunotherapy in cancer patients. J. Immunol. Methods. 1994;174:297–309
  65. Stevenson HC, Keenan AM, Woodhouse C, Ottow RT, Miller P, Steller EP, et al. Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. Cancer Res. 1987;47:6100–6103
  66. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, et al. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose IL-2 bolus treatment. Cancer Res. 1990;50:5795–5800
  67. Hennemann B, Beckman G, Eichelmann A, Rehm A, Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon-γ and lipopolysaccharide. Cancer Immunol. Immunother. 1998;45:250–256
  68. Hennemann B, Rehm A, Kottke A, Meidenbauer N, Andreesen R. Adoptive immunotherapy with tumour cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilised peripheral blood monocytes. J. Immunother. 1997;20:365–371

PII: S0145-2126(99)00189-7

Leukemia Research
Volume 24, Issue 4 , Pages 317-330 , April 2000

Article Tools

* Image Usage & Resolution